Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00001610-200505000-00012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effectiveness of surgical versus non-surgical interventions in treatment of digital mucous cysts.
Arch Dermatol Res
January 2025
Department of Dermatology, Oregon Health & Science University, 3303 S Bond Ave Building 1, 16th floor, Portland, OR, 97239, USA.
Construction of Double-layered DNA Tiles and Arrays from Double Crossover Motifs.
Chembiochem
January 2025
State Key Laboratory of Coordination Chemistry, School of Chemistry and Chemical Engineering, Nanjing University, 163 Xianlin Avenue, Nanjing, 210023, P. R. China E-amil.
DNA double crossover (DX) motifs including DAE (double crossover, antiparallel, even spacing) and DAO (double crossover, antiparallel, odd spacing) are well-known monolayered DNA building blocks for construction of 2D DNA arrays and tubes in nanoscale and microscale. Compared to the 3D architectures of DNA origami and single-stranded DNA bricks to build nanoscale 3D bundles, tessellations, gears, castles, etc., designs of double- and multi-layers of DX motifs for 3D architectures are still limited.
View Article and Find Full Text PDFMultiuser design of an architecture for social robots in education: teachers, students, and researchers perspectives.
Front Robot AI
December 2024
Robot Learning Laboratory, Instituto de Ciências Matemáticas e de Computação (ICMC), University of São Paulo (USP), SãoCarlos, Brazil.
Research on social assistive robots in education faces many challenges that extend beyond technical issues. On one hand, hardware and software limitations, such as algorithm accuracy in real-world applications, render this approach difficult for daily use. On the other hand, there are human factors that need addressing as well, such as student motivations and expectations toward the robot, teachers' time management and lack of knowledge to deal with such technologies, and effective communication between experimenters and stakeholders.
View Article and Find Full Text PDFEfficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study.
Dermatol Ther (Heidelb)
December 2024
Institute and Comprehensive Center Inflammation Medicine, University of Lübeck, Lübeck, Germany.
Introduction: Risankizumab has demonstrated superior efficacy compared to other psoriasis treatments, including secukinumab, adalimumab, and ustekinumab; switching to risankizumab from other psoriasis treatments has shown superior clinical and quality of life (QoL) outcomes. We evaluated the efficacy and safety of directly switching patients with moderate-to-severe plaque psoriasis and a suboptimal response to interleukin (IL)-17 inhibitors (secukinumab or ixekizumab) to risankizumab.
Methods: This 52-week, phase 3b study enrolled patients (≥ 18 years) with moderate-to-severe plaque psoriasis who had previously been treated with the recommended dose of secukinumab or ixekizumab for ≥ 6 months but did not achieve an optimal response (static Physician's Global Assessment [sPGA] 2/3; body surface are [BSA] 3- < 10%).
Retraction Note: Development and evaluation of rapid data-enabled access to routine clinical information to enhance early recruitment to the national clinical platform trial of COVID-19 community treatments.
Trials
October 2024
Nuffield Department of Primary Care Health Sciences, University of Oxford, Gibson Building 1St Floor, Radcliffe Observatory Quarter, Woodstock Road, Oxford, OX2 6GG, UK.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!